Welcoming Jim to our Board is a pleasure. His unique breadth of expertise in advancing technologies in heart failure and cardiorenal combined with his track record of capitalizing and positioning them to be the standard of care, through successful exit, fits perfectly with our strategy.
INDIANAPOLIS (Nov. 2, 2020) — FAST BioMedical, a privately held late clinical-stage medical technology company, today announces it has named Jim Dillon to its Board of Directors. Dillon is a former St. Jude Medical and Abiomed executive, with significant experience capitalizing and commercializing first-in-class heart failure and cardiorenal syndrome technologies.